Literature DB >> 35653592

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.

Elias Campo1, Elaine S Jaffe2, James R Cook3, Leticia Quintanilla-Martinez4, Steven H Swerdlow5, Kenneth C Anderson6, Pierre Brousset7, Lorenzo Cerroni8, Laurence de Leval9, Stefan Dirnhofer10, Ahmet Dogan11, Andrew L Feldman12, Falko Fend4, Jonathan W Friedberg13, Philippe Gaulard14,15, Paolo Ghia16, Steven M Horwitz17, Rebecca L King12, Gilles Salles17, Jesus San-Miguel18, John F Seymour19, Steven P Treon6, Julie M Vose20, Emanuele Zucca21, Ranjana Advani22, Stephen Ansell23, Wing-Yan Au24, Carlos Barrionuevo25, Leif Bergsagel26, Wing C Chan27, Jeffrey I Cohen28, Francesco d'Amore29, Andrew Davies30, Brunangelo Falini31, Irene M Ghobrial6,32, John R Goodlad33, John G Gribben34, Eric D Hsi35, Brad S Kahl36, Won-Seog Kim37, Shaji Kumar23, Ann S LaCasce6, Camille Laurent7, Georg Lenz38, John P Leonard39, Michael P Link40, Armando Lopez-Guillermo41, Maria Victoria Mateos42, Elizabeth Macintyre43, Ari M Melnick44, Franck Morschhauser45, Shigeo Nakamura46, Marina Narbaitz47, Astrid Pavlovsky48, Stefano A Pileri49, Miguel Piris50, Barbara Pro51, Vincent Rajkumar12, Steven T Rosen52, Birgitta Sander53, Laurie Sehn54, Margaret A Shipp6, Sonali M Smith55, Louis M Staudt56, Catherine Thieblemont57,58, Thomas Tousseyn59, Wyndham H Wilson56, Tadashi Yoshino60, Pier-Luigi Zinzani61, Martin Dreyling62, David W Scott54, Jane N Winter63, Andrew D Zelenetz17,64.   

Abstract

Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.

Entities:  

Mesh:

Year:  2022        PMID: 35653592     DOI: 10.1182/blood.2022015851

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  4 in total

Review 1.  New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders.

Authors:  Leticia Quintanilla-Martinez; Steven H Swerdlow; Thomas Tousseyn; Carlos Barrionuevo; Shigeo Nakamura; Elaine S Jaffe
Journal:  Virchows Arch       Date:  2022-10-11       Impact factor: 4.535

Review 2.  Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.

Authors:  Taishi Takahara; Akira Satou; Toyonori Tsuzuki; Shigeo Nakamura
Journal:  Diagnostics (Basel)       Date:  2022-06-20

Review 3.  Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.

Authors:  Jérôme Paillassa; Elsa Maitre; Xavier Troussard
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

4.  Expression and Significance of Cyclin-Dependent Protein Kinase 6 in Diffuse Large B-Cell Lymphoma.

Authors:  Jing Li; Peng Li; Hong Su; Haonan Feng; Zhongyuan Bai; Yanfeng Xi
Journal:  Int J Gen Med       Date:  2022-09-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.